NOVO.TO Novo Nordisk CDR (CAD Hedged)

Healthcare Drug Manufacturers - General Toronto Exchange
- CAD
Market cap
-
P/E
10.2x
P/B
1.74x
ROE
-
Dividend yield
2.42%
Fundamental score
-

Is NOVO.TO undervalued?

Graham number

The Graham number of Novo Nordisk CDR (CAD Hedged) cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Novo Nordisk CDR (CAD Hedged) fundamental analysis

No fundamental analysis for Novo Nordisk CDR (CAD Hedged) yet.

Novo Nordisk CDR (CAD Hedged) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Novo Nordisk CDR (CAD Hedged)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segm…

Full company profile